2019
DOI: 10.1037/pha0000275
|View full text |Cite
|
Sign up to set email alerts
|

Repeated subcutaneous administration of PT150 has dose-dependent effects on sign tracking in male Japanese quail.

Abstract: The main findings from the current study are that the glucocorticoid receptor antagonist PT150 dose dependently reduces sign tracking. Because persistent sign tracking behavior is associated with drug relapse, the ability to reduce it may contribute to drug addiction treatment. Potential pharmacological treatments that alter the glucocorticoid stress system may be of significance for drug addiction research.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
14
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
3
1

Relationship

1
9

Authors

Journals

citations
Cited by 12 publications
(16 citation statements)
references
References 32 publications
1
14
1
Order By: Relevance
“…Further, lesions of the ventral, but not the dorsal, hippocampus decrease the propensity to sign-track ( Fitzpatrick et al, 2016 ). While it is remains to be determined whether these lesion effects are dependent on GR function, it should be noted that systemic administration of a GR antagonist similarly attenuates the acquisition of sign-tracking behavior ( Rice et al, 2018 , 2019 ).…”
Section: Discussionmentioning
confidence: 99%
“…Further, lesions of the ventral, but not the dorsal, hippocampus decrease the propensity to sign-track ( Fitzpatrick et al, 2016 ). While it is remains to be determined whether these lesion effects are dependent on GR function, it should be noted that systemic administration of a GR antagonist similarly attenuates the acquisition of sign-tracking behavior ( Rice et al, 2018 , 2019 ).…”
Section: Discussionmentioning
confidence: 99%
“…However, higher dosing would be necessary to specify if an actual CC50, if any cytotoxicity can be identified. As already noted, no significant cytotoxicities were identified in the compound's extensive pre-clinical and clinical (phase 1, 2) studies [6,[13][14][15][16][17][18].…”
Section: Discussionmentioning
confidence: 99%
“…In support, lesions of the ventral, but not the dorsal, hippocampus decrease the propensity to sign-track (Fitzpatrick et al, 2016). While it is remains to be determined whether these lesion effects are dependent on GR function, it should be noted that systemic administration of a GR antagonist similarly attenuates the acquisition of sign-tracking behavior (Rice et al, 2018; Rice et al, 2019). Taken together, GR function, and presumably that within the ventral hippocampus, appears to play an important role in incentive motivational processes.…”
Section: Discussionmentioning
confidence: 99%